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To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD),
paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two
patients with advanced-stage solid tumours were treated with escalated doses of PLD on day 1 and PCX plus GEM on day 2 (starting
doses: 10, 100 and 800mgm
 2, respectively) every 2 weeks. DLTs and pharmacokinetic (PK) parameters of all drugs were
determined during the first cycle of treatment. All but six (73%) patients had previously received at least one chemotherapy regimen.
The DLT dose level was reached at PLD 12mgm
 2, PCX 110mgm
 2 and GEM 1000mgm
 2 with neutropaenia being the dose-
limiting event. Of the 86 chemotherapy cycles delivered, grade 3 and 4 neutropaenia occurred in 20% with no cases of febrile
neutropaenia. Non-haematological toxicities were mild. The recommended MTDs are PLD 12mgm
 2, PCX 100mgm
 2 and GEM
1000mgm
 2 administered every 2 weeks. The PK data revealed no obvious drug interactions. Biweekly administration of PLD, PCX
and GEM is a well-tolerated chemotherapy regimen, which merits further evaluation in various types of solid tumours.
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Chemotherapy regimens combining paclitaxel (PCX) with doxo-
rubicin have shown high antitumour activity in breast, ovarian,
AIDS-related Kaposi’s sarcoma and other types of tumours.
However, their combination has been associated with severe
haematological and cardiac toxicity in patients with metastatic
breast cancer (MBC) (Gianni et al, 1995; Gehl et al, 1996; Sparano
et al, 1999). Indeed, up to 50% of patients receiving the PCX/
doxorubicin combination developed a reduction in the left
ventricular ejection fraction (LVEF) below the normal level and
20% of them developed congestive heart failure (Gianni et al, 1995;
Gehl et al, 1996). Several studies have suggested a sequence-
dependent tolerability because of altered pharmacokinetics (PKs)
when PCX precedes doxorubicin administration (Holmes et al,
1996; Gianni et al, 1997).
In an effort to reduce toxicity while maintaining the same level of
activity, doxorubicin has been entrapped in liposomes. Pegylated
technology represents a favourable drug carrier system, since stealth
liposomal drugs have a reduced clearance with prolonged circulation
half-life. The size and structure of stealth liposomes prevent drug
extravasation, resulting in selective drug accumulation in tissues with
increased vascular permeability, such as tumour tissues, whereas its
concentration in the cardiac muscle remains low (Working et al,
1994). Caelyx or Doxil (pegylated liposomal doxorubicin (PLD)) is a
long-circulating pegylated liposome-containing doxorubicin, which
has been developed to target drug delivery to cancer cells, while
reducing the toxicities associated with the free doxorubicin. Clinical
trials have shown that PLD has significant activity in various types of
tumours, with dose-dependent, cumulative and reversible palmar-
plantar erythrodysesthesia (PPE) and mycositis being the main dose-
limiting toxicities (DLTs) (Uziely et al, 1995; Muggia et al, 1997),
while myelosuppression, nausea, alopecia and cardiotoxicity are less
common and severe compared to free doxorubicin (Berry et al,1 9 9 8 ;
Safra et al, 2000).
Gemcitabine (GEM), a novel S-phase-specific cytidine nucleo-
side analogue of deoxycytidine, has been shown to have a broad
antitumour activity against breast, lung, ovarian, bladder and
pancreatic cancer (Merriman et al, 1996). Its toxicity profile is
acceptable, with the main toxicity being mild myelosuppression of
short duration. In general, GEM’s favourable single-agent activity
and novel mechanisms of action, in addition to its largely non-
overlapping toxicities, have facilitated its combination with a
variety of chemotherapy agents, including the taxanes. Several
phase I and II trials have reported impressive activity for the GEM/
taxane doublet with a suggestion of clinical synergism between
these two classes of agents (Colomer, 2004). A recent phase III
randomised trial showed a clear advantage for GEM plus PCX over
PCX alone, as first-line treatment of MBC, in time to disease
progression, objective response rate and overall survival (Albain
et al, 2004). In addition, the GEM/anthracycline (epirubicin,
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sdoxorubicin, PLD) combination seems to be well tolerated with
promising activity in solid tumours (Rivera et al, 2003; Fabi et al, 2006).
Chemotherapy regimens combining PCX with PLD, PCX with
GEM and GEM with PLD have shown antitumour activity
and favourable non-overlapping toxicity in various tumours
(Androulakis et al, 2002; Mavroudis et al, 2002). In addition, the
triplet combination of PCX, epirubicin and GEM was active against
MBC, but it was associated with a high (about 60%) incidence of
grade 3 and 4 neutropaenia and, to a lesser extent, cardiotoxicity
(Sanchez-Rovira et al, 2000; Conte et al, 2001; Cappuzzo et al,
2004; Zielinski et al, 2005). In order to improve the toxicity profile
of the triple combination of PCX plus PLD plus GEM by reducing
the dose-dependent toxicities and allowing sufficient time to
recover between treatments, a biweekly regimen was developed
and evaluated in a phase I study.
PATIENTS AND METHODS
Patient selection
Patients with histologically or cytologically confirmed advanced-
stage solid tumours, for which there is no effective therapy or
who had relapsed after receiving the ‘standard’ first-line treatment,
were enrolled onto the study. Prior surgery, radiotherapy (to
o20% of bone marrow containing bones) or chemotherapy
(maximum two prior regimens) were allowed, but a treatment-
free interval of at least 4 weeks was required before entering
the study. Other inclusion criteria were: age 418 years, a World
Health Organization (WHO) performance status of 0–2, a life
expectancy of at least 3 months, an adequate bone marrow
(absolute neutrophil count 41500dl
 1,H b410gdl
 1, platelets
4100000dl
 1), renal (serum creatinine o1.5mgdl
 1), liver (total
bilirubin o1.5mgdl
 1 and SGOT/SGPT o2 times the upper
normal values) and cardiac (normal baseline LVEF by multiple
gated acquisition (MUGA) scan or echocardiogram) function and
pre-existing peripheral neuropathy pgrade (WHO) 1. Additional
inclusion criteria were: absence of an active infection or severe
malnutrition (loss 420% of the body weight during the last 3
months) and absence of any psychological or social condition
potentially hampering compliance with the study protocol.
Patients with brain metastases were allowed to participate if they
had been irradiated with clinical and/or radiographical improve-
ment, while patients with prior history of congestive heart failure
or active and uncontrolled coronary disease were not eligible. The
presence of measurable disease was not required. All patients gave
written informed consent to participate in the study, which has
been approved by the Ethics and Scientific Committees of our
Institution.
Treatment plan
Escalated doses of PLD (Caelyx; Schering Plough Pharmaceuticals,
Kenilworth, NJ, USA) (starting dose: 10mgm
 2 with increments
of 2mgm
 2) were administered as a 30-min intravenous (i.v.)
infusion on day 1, and PCX (Taxol; Bristol-Myers Squibb Co.,
Princeton, NJ, USA) (starting dose: 100mgm
 2 with increments of
10mgm
 2) as a 3-h i.v. infusion followed by GEM (Gemzar;
Eli Lilly, Indianapolis, IN, USA) (starting dose: 800mgm
 2 with
increments of 200mgm
 2) as 30-min i.v. infusion on day 2. The
regimen was repeated every 2 weeks without growth factor support
in cycles of 4 weeks. Premedication for PCX consisted of
dexamethasone 20mg orally 14 and 7h before treatment,
ranitidine 300mg i.v. and diphenhydramine 50mg i.v. 30min
before treatment. The prophylactic anti-emetic regimen included
ondansetron 16mg and dexamethasone 8mg given i.v. 30min
before chemotherapy. The treatment was administrated on
scheduled days if the absolute neutrophil count was 41500dl
 1,
platelets 4100000dl
 1, and all the other toxicities had resolved to
grade p1. Otherwise, treatment was postponed until the resolution
of all toxicities and, then, was restarted with dose reduction at the
previous dose level. Doses were also reduced at the previous dose
level in case of febrile neutropaenia or platelet transfusion. Patients
requiring more than 2 weeks treatment delay for any reason or
experiencing a decrease of the LVEF 415% below the baseline
values with or without clinical signs of congestive heart failure
were withdrawn from the study. Patients who developed DLTs at
any cycle of the treatment, received the same treatment but dosed
at the previous dose level. Patients continued treatment until
prohibitive toxicity, disease progression, achievement of maximal
response or consent withdrawn.
Dose escalation
The following dose levels (mgm
 2) for the PLD/PCX/GEM
combination have been evaluated: 10/100/800, 12/100/800, 12/
100/1000 and 12/110/1000. No intrapatient dose escalation was
allowed. At least three patients were enrolled at each dose level. If
DLT was observed in one of the three patients, three additional
patients were treated with the same doses. All patients were
assessed for dose-limiting events during the first chemotherapy
cycle. The DLT was defined as the occurrence of any of the
following events: grade 4 neutropaenia or thrombocytopaenia,
febrile neutropaenia, any grade X3 non-haematological toxicity
except for nausea/vomiting and any treatment delay 42 days due
to unresolved haematological or non-haematological toxicity. If at
least 50% of the patients at a certain dose level experienced DLT,
the study was completed and the maximum tolerated dose (MTD)
level, which is recommended for further phase II studies, was the
previous level before the DLT dose level (Socinski et al, 2001).
Patients’ evaluation
Baseline evaluations included: patient history, physical examina-
tion, complete blood count with differential and platelet count,
serum chemistry, chest X-rays, electrocardiogram, echocardiogra-
phy or MUGA scan with LVEF measurement, thorax and abdomen
computed tomography scans and whole body bone scintigraphy.
Complete blood counts were performed weekly for all patients
or in case of grade 3 and 4 haematological toxicity daily
until recovery. Serum chemistry as well as a detailed toxicity
questionnaire and a physical examination were performed before
each treatment administration. The LVEF was measured at
baseline and every 3 chemotherapy cycles in percentage (%)
(normal values 445%). Disease status was assessed every 3 cycles
or earlier in case of clinical evidence of disease progression.
Toxicities were graded according to the National Cancer Institute
(NCI) Common Toxicity Criteria version 2.0, and evaluation of
response was performed according to the WHO criteria (Miller
et al, 1981). All patients receiving at least one cycle of treatment
were evaluable for toxicity and patients with bidimensionally
measurable disease receiving at least three chemotherapy cycles
were evaluable for response. After treatment, patients were
followed monthly until disease progression by physical examina-
tion, blood tests, serum chemistry and any other test that the
responsible physician considered necessary.
Pharmacokinetic study
Samples for measurement of plasma levels of doxorubicin, PCX
and GEM were obtained during cycle 1. Blood samples (5ml each)
were taken from an antecubital vein contralateral to the site of
injection. Sampling for PLD was set before drug administration
and at 1, 6, 24, 72 and 168h after the beginning of infusion. PCX
administration started on the second day of the treatment followed
by GEM infusion. Samples for PCX were collected before and at 1,
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s3, 4, 6, 10 and 24h after the beginning of drug infusion. GEM
sampling was performed in tubes containing tetrahydrouridine
before drug administration, at 30, 45min and 1, 1.5, 4.5h after the
beginning of GEM infusion.
Doxorubicin plasma samples were measured using a reverse-
phase high-performance liquid chromatographic (HPLC) method
according to Gabizon et al (1994). Briefly, 400ml isopropanol,
400ml chloroform, 0.5g ammonium sulphate and internal standard
(daunorubucin) were added to 400ml of each plasma sample.
The mixture was centrifuged at 10000r.p.m. for 15min and the
supernatant evaporated to dryness under a stream of nitrogen at
301C. Concentrated samples were reconstituted in 200ml isopro-
panol and 50ml was injected into the HPLC within 24h. The mobile
phase consisted of acetonitrile:water (4:6 vv
 1) adjusted to pH
2.60 with perchloric acid. Analysis was performed on a reverse-
phase Lichrospher RP-8 column (150 4.6mm, 5mm MZ-Analy-
setechnik GmbH, Mainz, Germany). Doxorubicin was monitored
at 470nm excitation and 590nm emission wavelengths with
fluorescence detector. Standard calibration curve was linear in
the range 0.10–12.50mgml
 1 (r
2X0.998) with a lower limit of
quantitation (LOQ) of 0.05mgml
 1.
For PCX measurements, 100ml of internal standard (docetaxel)
and 5ml of acetonitrile:n-butylchloride (1:4 vv
 1) were added to
1ml of human plasma based on a method described by Sparreboom
et al (1998). The organic layer was collected and evaporated to
dryness under a stream of nitrogen at 601C. The residue was
reconstituted in 125mlo fm e t h a n o l : w a t e r( 1 : 1v v
 1)a n du l t r a -
sonicated for 1min. A 100ml portion of the solution was injected to
HPLC system. The chromatographic analysis was achieved in an
Inertsil ODS-80A column (150 4.6mm, 5mm; GL Science Inc.,
Tokyo, Japan) at 601C. Mobile phase was a solution of water:
methanol:tetrahydrofuran:ammonium hydroxide (37.5:60:2.5:0.1
vv
 1) adjusted to pH 6.0 with formic acid. Flow rate was set at
1mlmin
 1 and detection of PCX was achieved at 230nm with an
ultraviolet detector. Calibration curve was prepared in blank human
plasma with standard concentrations of PCX over the range of 0.01–
2.0mgml
 1 (r
2X0.9993). The LOQ was determined at 0.01mgml
 1.
Measurements of GEM plasma samples were performed with a
reverse-phase HPLC method, as described previously (Mavroudis
et al, 2003). GEM was assayed in a reversed-phase column
m-Bondapack C18 (300 3.9mm, 10mm Waters, Milford, MA,
USA) and monitored at 267nm with ultraviolet detector. The linear
range of the assay was established at 0.1–10mgml
 1 (r
2X0.9998)
and the LOQ was set at 0.078mgml
 1 of plasma.
Doxorubicin, PCX and GEM were assayed on an LC-10A/10Avp
Shimadzu chromatographic system (Shimadzu Deutchland GmbH,
Duisburg, Germany) equipped with an RF-10Axl fluorescence
detector and an SPD-M10Avp ultraviolet detector. PK parameters
for doxorubicin, PCX and GEM were estimated by the non-
compartmental method using WinNonlin (Standard edition
version 2.1) program (Pharsight Co., Palo Alto, CA, USA).
RESULTS
Patients’ demographics
From October 2002 to January 2004, 22 patients with advanced-
stage solid tumours were enrolled onto the study. All patients were
evaluable for toxicity. Median age was 64 years, the performance
status (WHO) was 0–1 in 91% of patients, and 16 (73%) of them
had received, at least, one prior chemotherapy regimen. Patients’
characteristics are shown in Table 1.
Dose-limiting toxicities
The administration of two biweekly consecutive treatments
(4 weeks) was considered as one treatment cycle. Table 2 shows the
dose escalation levels, the number of patients enrolled at each dose
level and the observed DLTs during the first cycle of treatment.
The main toxicity observed during the first chemotherapy cycle
was neutropaenia; indeed, two patients developed grade 4
neutropaenia and five patients grade 3 (n¼2 patients) or grade
2( n¼2 patients) neutropaenia and grade 2 (n¼1 patient)
anaemia leading to treatment delay for more than 2 days. At the
dose level IV where an additional patient was enrolled because of
an initial doubt about the characterisation of toxicity, three out of
four patients developed DLTs (one patient grade 4 neutropaenia
and two patients treatment delays because of grade 2 and 3
neutropaenia), and therefore, this was considered as the DLT level.
The MTDs which are the doses recommended for future phase II
studies were PLD 12mgm
 2 on day 1 and PCX 100mgm
 2
followed by GEM 1000mgm
 2 on day 2 every 2 weeks without
growth factor support. Three additional patients were treated
at the MTD dose level without the occurrence of any additional
dose-limiting event (Table 2).
Haematological and non-haematological toxicities
Eighty-six chemotherapy cycles were administered with a median
of three cycles/patient (range, 1–9). Twenty-one (24%) cycles were
delayed because of haematological toxicity (n¼9 cycles; 10.5%)
and late admission for reasons unrelated to the disease or
treatment (delays for imaging evaluations, n¼12; 14%). Table 3
shows the number of chemotherapy cycles complicated with grade
2–4 toxicities and Table 4 shows the worst grade 2–4
haematological and non-haematological toxicities per patient by
Table 1 Patients’ characteristics
No. of patients (%)
Patients enrolled 22
Evaluable for toxicity 22
Evaluable for response 18
Age (years)
Median (range) 64 (40–77)
Gender
Male/female 8/14 36/64
Performance status (WHO)
07 3 2
11 3 5 9
22 9
Previous chemotherapy regimens
06 2 7
16 2 7
21 0 4 6
Previous treatment
Surgery 18 82
Adjuvant chemotherapy 8 36
Neo-adjuvant chemotherapy 1 5
Chemotherapy for metastatic disease 16 73
Adjuvant radiotherapy 7 32
Radiotherapy for metastatic disease 4 18
None 1 5
Type of tumour
Breast cancer 9 41
Lung cancer 2 9
Bladder cancer 3 14
Ovarian cancer 2 9
Cancer of unknown primary 1 5
Other 5 23
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sdose-level, during all cycles. Overall, the haematological toxicity of
the regimen was acceptable since 14 (16%) and 3 (4%) cycles out of
the 86 cycles administered were complicated with grade 3 and 4
neutropaenia, respectively. No grade 4 anaemia or thrombocyto-
paenia was observed. One patient, at the dose level IV, developed
grade 3 anaemia, and another one, at the dose level III, developed
grade 3 thrombocytopaenia (Table 4).
The most common non-haematological toxicity was grade 2
asthenia complicating 19% of the cycles; the incidence of other
non-haematological toxicities were rare (o5%) and mild (pgrade
2; Table 3). There was no clinically relevant moderate or severe
PPE while there was no patient who presented a reduction of LVEF
410% of the baseline values or congestive heart failure. Owing to
the toxicities observed, 21 (24%) of the treatment cycles were
delayed and another 6 (7%) were given with a dose reduction. The
median duration of treatment delay was 9 days (range, 4–31 days)
for all cycles. The median cumulative dose administered was
604mgm
 2 (range, 111–1800mgm
 2) for PCX, 71mgm
 2 (range,
11.9–186mgm
 2) for PLD and 5564mgm
 2 (range, 1000–
14376mgm
 2) for GEM. All patients have discontinued treatment
for the following reasons: progressive disease (n¼9 patients),
completion of treatment (n¼9 patients), consent withdrawn
(n¼2 patients) and neutropaenia (n¼2 patients).
Pharmacokinetics
The effects of dose escalation on the PK parameters of the
combination are shown in Table 5. The PKs of PLD were
characterised by Cmax ranging from 5.51 to 7.78mgl
 1, with a
typically slow post-infusional elimination with half-life values
ranging between 38.52 and 63.44h, and CL from 0.018 to
0.059lh
 1. The areas under the curve for all time points (AUCall)
were similar to those extrapolated to infinity (AUCinf) (range:
208.07–514.18 and 222.02–670.12mghl
 1, respectively), while the
value of Vz ranged between 1.65 and 3.62l. PK of PCX were defined
by Cmax varying from 0.96 to 1.65mgl
 1, detected at the end of the
drug infusion (tmax, 3h), and by an elimination with t1/2 and
CL values ranging from 2.82 to 5.09h and 0.016 to 0.028lh
 1,
respectively; the AUCall estimated from concentration–time data
were between 3.67 and 6.18mghl
 1 (Table 5). The PK profile of
GEM presented a dose escalated change from level II to III of Cmax
(4.46–12.27mgl
 1) achieved at the end of infusion (tmax, 0.50h),
AUCall (2.95–7.26mghl
 1), AUCinf (2.66–6.80mghl
 1) and CL
(323.64–160.01lh
 1).
Response to treatment
Eighteen patients with bidimensionally measurable disease were
evaluable for response. One patient achieved a partial response and
nine patients stable disease. The partial response occurred in a
patient with carcinoma of unknown primary site receiving first-
line treatment at the dose level III. The duration of response was
8.7 months and the median time to tumour progression for the
whole group of patients was 4.5 months (range, 1.0–16.5 months).
Regarding the nine breast cancer patients who were enrolled
onto the study, they received the study regimen as first-line (n¼2
patients), second-line (n¼2 patients) and third-line treatment
(n¼5 patients). Additionally, none of the four non-evaluable for
Table 3 Cycles of chemotherapy complicated by grade 2–4 haematological and non-haematological toxicities
Dose
level Cycles
Neutropaenia
grade 2/3/4
Anaemia
grade 2/3/4
Thrombocytopaenia
grade 2/3/4
Nausea/vomiting
grade 2/3/4
Diarrhoea
grade 2/3/4
Mucositis
grade 2/3/4
Neurotoxicity
grade 2/3/4
Asthenia
grade 2/3/4
I 15 1/2/  4/ /   / /   / /   / /   / /   / /  6/ / 
II 22 6/4/  4/ /   / /  1/ /  2/1/  1/ /   / /   / / 
III 36 7/5/2 5/ /   /1/  3/ /   / /  2/ /  3/ /  10/ / 
IV 13 3/3/1 2/1/  1/ /   / /   / /   / /   / /   / / 
Table 4 Worst (grades 2–4) haematological and non-haematological toxicities per patient during all cycles
Dose
level Patients
Neutropaenia
grade 2/3/4
Anaemia
grade 2/3/4
Thrombocytopaenia
grade 2/3/4
Nausea/vomiting
grade 2/3/4
Diarrhoea
grade 2/3/4
Mucositis
grade 2/3/4
Neurotoxicity
grade 2/3/4
Asthenia
grade 2/3/4
I3  /2/  2/ /   / /   / /   / /   / /   / /  1/ / 
II 6 1/2/  3/ /   / /  1/ /  2/1/  1/ /   / /   / / 
III 9 2/2/1 3/ /   /1/  3/ /   / /  1/ /  2/ /  4/ / 
IV 4 1/2/1  /1/  1/ /   / /   / /   / /   / /   / / 
Table 2 Dose escalation levels, number of patients enrolled and DLTs during the first cycle
Dose level PLD (mgm
 2)P C X ( m g m
 2) GEM (mgm
 2) Patients enrolled DLT (number of patients)
I 10 100 800 3 —
II 12 100 800 6 Grade 3 neutropaenia
a (1)
Grade 2 neutropaenia
a (1)
III 12 100 1000 9 Grade 4 neutropaenia (1)
Grade 2 anaemia
a (1)
IV 12 110 1000 4 Grade 4 neutropaenia (1)
Grade 3 neutropaenia
a (1)
Grade 2 neutropaenia
a (1)
DLT¼dose-limiting toxicity.
aThe toxicity was considered a ‘DLT’ because it resulted in treatment delay.
Phase I PCX, PLD and GEM in solid tumours
V Bozionelou et al
46
British Journal of Cancer (2007) 97(1), 43–49 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sresponse patients discontinued treatment due to disease progres-
sion. Two of them discontinued due to neutropaenia and the other
two, although have completed the treatment, were considered non-
evaluable for response because they had non-measurable disease.
DISCUSSION
Doxorubicin is one of the most widely used anticancer drugs but
despite its excellent antitumour activity, its use is limited by drug-
associated toxicities, particularly myelosuppression and cardio-
toxicity. The combination of PCX and anthracyclines has been also
evaluated in several trials using a variety of doses and adminis-
tration schedules, with studies showing drug interaction with
respect to disposition and toxicity. Indeed, the PK studies of
doxorubicin in regimens containing PCX have demonstrated that
the schedule-dependent increase in Cmax and AUC and the
reduction in doxorubicin clearance were associated with severe
neutropaenia and mucositis (Holmes et al, 1996) as well as cardiac
toxicity (Gianni et al, 1997). Furthermore, the addition of GEM
to the PCX/anthracycline combination was associated with an
increased incidence of severe neutropaenia ranging from 62 to 72%
of patients (Sanchez-Rovira et al, 2000; Conte et al, 2001;
Cappuzzo et al, 2004; Zielinski et al, 2005).
In order to improve the toxicity profile of the combination of
PCX with anthracyclines, PLD was substituted for doxorubicin or
epirubicin and the regimen was administered on a biweekly basis;
this phase I study indicated that the regimen was very well
tolerated with treatment delay due to grade 2 and 3 neutropaenia
to be the dose-limiting event (Mavroudis et al, 2002). Based on the
favourable toxicity profile of the biweekly administration of PCX
and PLD and in an effort to further develop this schedule,
GEM was added to the PCX/PLD combination in this phase I
trial to determine the MTD and the DLT of the combination.
Grade 4 neutropaenia (two cases) and grade 2/3 neutropaenia
and anaemia resulting in treatment delays on days 15 or 28 were
the dose-limiting events observed in this study. Accordingly, the
recommended doses for future phase II studies were PLD
12mgm
 2 on day 1 and PCX 100mgm
 2 followed by GEM
1000mgm
 2 on day 2 administered every 2 weeks without growth
factor support.
In the present study, there was no need for the prophylactic use
of growth factor since clinically relevant neutropaenia was rare.
Conversely, in a study by Sanchez-Rovira et al (2000) almost 60%
of the cycles required support with granulocyte colony-stimulating
factor. In addition, none of the patients in our study developed
febrile neutropaenia. Grade 2 asthenia was the most common non-
haematological toxicity resulting in the discontinuation of treat-
ment in one patient. However, since the majority of patients
experienced progressive disease, it is not clear whether asthenia
was attributed exclusively to the chemotherapy regimen.
Skin and mucosal toxicities are frequent adverse events of
PLD. These adverse events are dose- and schedule-related with
stomatitis being more frequent and severe at higher doses, while
shorter dosing intervals lead to an increased incidence and severity
of skin manifestations. However, in the present study, mucositis, a
relatively frequent adverse event of PCX plus anthracycline plus
GEM combination (Sanchez-Rovira et al, 2000; Conte et al, 2001;
Zielinski et al, 2005), as well as PPE, were mild and uncommon.
Moreover, neurotoxicity or cardiac toxicity, which already have
been reported to complicate the PCX plus epirubicin plus GEM
regimen (Sanchez-Rovira et al, 2000; Zielinski et al, 2005), were
not observed in the present study.
This favourable toxicity profile of the PLD/PCX/GEM combina-
tion should be, mainly, attributed to both the substitution of free
anthracycline for PLD and the low cumulative dose of PLD. Indeed,
its formulation protects the liposomes from detection by the
mononuclear phagocyte system, thus increasing its circulation
time and allowing for more targeted delivery of doxorubicin to the
tumour cells (Working et al, 1994). The comparison of PLD to
conventional doxorubicin, as first-line treatment of patients with
MBC revealed that the two drugs were broadly comparable in
terms of efficacy, but PLD had a different safety profile with
significantly reduced cardiac toxicity including those subgroups of
patients at increased risk of developing a cardiac event; conversely,
there was a higher incidence of skin toxicity (PPE) and less
alopecia, nausea, vomiting and myelosuppression with PLD than
with conventional doxorubicin (O’Brien et al, 2004).
Table 5 Means (7s.d.) of pharmacokinetic parameters at different dose levels of the PLD/PCX/GEM combination
Dose levels
(no. of patients) I (2) II (2) III (6) IV (3)
PLD tmax (h) 1.0 1.0 3.0 4.3
Cmax (mgl
 1) 6.3071.94 5.5170.36 7.7871.42 6.8570.64
t1/2 (h) 38.5272.11 47.16711.07 63.44711.67 48.75714.03
AUCall (mghl
 1) 208.07768.76 210.40772.03 514.187102.24 428.81789.28
AUCinf (mghl
 1) 222.02771.57 241.90795.05 670.127100.52 501.36799.47
Vz (l) 2.8471.05 3.6270.63 1.6570.27 1.7870.44
CL (lh
 1) 0.05070.016 0.05970.023 0.01870.003 0.02570.005
PCX tmax (h) 3.0 3.0 3.0 3.0
Cmax (mgl
 1) 1.6570.12 0.9670.05 1.1670.34 1.4670.06
t1/2 (h) 5.0970.43 2.8271.64 3.5571.62 4.1971.49
AUCall (mghl
 1) 6.1870.75 3.6770.62 4.5071.03 5.8370.29
AUCinf (mghl
 1) 6.4970.88 3.7070.71 4.5871.11 5.9470.62
Vz (l) 0.11470.006 0.10170.044 0.11270.051 0.10970.031
CL (lh
 1) 0.01670.002 0.02870.005 0.02370.005 0.01970.002
GEM tmax (h) ND 0.50 0.50 0.58 (0.50–0.75)
Cmax (mgl
 1) ND 4.4670.80 12.2773.28 10.4672.23
t1/2 (h) ND 0.2670.07 0.3670.18 0.4870.35
AUCall (mghl
 1) ND 2.9571.02 7.2671.89 8.5571.08
AUCinf (mghl
 1) ND 2.6670.71 6.8071.65 8.1571.72
Vz (l) ND 111.8470.74 91.75778.04 77.80741.38
CL (lh
 1) ND 323.64786.33 160.01754.59 128.03725.80
GEM¼gemcitabine; ND¼not determined; PCX¼paclitaxel; PLD¼pegylated liposomal doxorubicin.
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evaluate the PK profile of different dose levels of the PLD/PCX/
GEM combination. PK analysis demonstrated that the studied
combination did not produce any major changes since all studied
parameters were found to be in accordance with other published
reports (Lyass et al, 2000; Ichiki et al, 2003). Patients at dose level
III presented significant changes in some PK parameters of PLD
that cannot be associated with the administration of the other two
drugs since that effect appeared on PLD-monotherapy day (first
day of the cycle) and before PCX and GEM administration (PLD
tmax for dose level III: 3h). Studies on gender-dependent
differences of doxorubicin have already been reported (Clements
et al, 2002; Suzuki et al, 2006). In the present study, five out of six
patients at dose level III were females implying that gender-related
effects could be the most possible explanation for the observed
differences in the PK parameters of PLD. Finally, dose escalation
of GEM (800–1000mgm
 2) and PCX (100–110mgm
 2) were
the reasons for the PK changes observed between dose levels II and
III/IV for GEM and dose levels III and IV for PCX (Table 5). Based
on the above PK data, no obvious drug–drug interactions were
observed.
Based on previous observations of considerable activity and
limited toxicity of GEM as first-, second- and even third-line
treatment in phase II studies of MBC (Seidman, 2003), the addition
of GEM to epirubicin and PCX was speculated to increase activity
of the combination without additional toxicity. Thus, a combina-
tion regimen of GEM, epirubicin and PCX (GET) was developed,
which has shown a response rate of 92% in a phase II study of
patients with MBC (Conte et al, 2001). However, in a recent phase
III trial the GET regimen failed to demonstrate superiority over
FEC and at the same time had a higher toxicity (Zielinski et al,
2005). Moreover, combination chemotherapy has resulted in
similar efficacy as sequential single-agent therapy in MBC (Sledge
et al, 2003). Therefore, it remains to be tested if any triplet
combination is superior to the sequential administration of the
corresponding single agents.
The low-response rate observed in our study (only 1 in 18
evaluable patients presented a partial response) may be due to the
advanced line of treatment, since most of the patients were heavily
pretreated, as well as to the short treatment period (median of
three cycles/patient).
In conclusion, the current phase I study clearly demonstrates
that the triplet combination of PLD plus PCX and GEM given every
2 weeks is a well-tolerated regimen, which merits further
evaluation in phase II studies in patients with sensitive tumours
such as breast, ovarian or head and neck cancer. However, any
clinical application of this regimen should be weighted against the
increased cost of treatment.
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